Pre-erythrocytic malaria vaccines target Plasmodium during its sporozoite and liver stages,
and can prevent progression to blood-stage disease, which causes a million deaths each …

The parasitic disease malaria threatens more than 3 billion people worldwide, resulting in
more than 200 million clinical cases and almost 600,000 deaths annually. Vaccines remain …

Tissue-resident memory CD8+ T (Trm) cells in the liver are critical for long-term protection
against pre-erythrocytic Plasmodium infection. Such protection can usually be induced with …

CD8+ T cells mediate immunity against Plasmodium liver stages. However, the paucity of
parasite-specific epitopes of CD8+ T cells has limited our current understanding of the …

Introduction A safe and effective vaccine will likely be necessary for the control or
eradication of malaria which kills 400,000 annually. Our most advanced vaccine candidate …

Background Nearly 100% protection against malaria infection can be achieved in humans
by immunization with P. falciparum radiation-attenuated sporozoites (RAS). Although it is …

Development of an antimalarial subunit vaccine inducing protective cytotoxic T lymphocyte
(CTL)-mediated immunity could pave the way for malaria eradication. Experimental …

Vaccines targeting the complex pre-erythrocytic stage of Plasmodium parasites may benefit
from the inclusion of multiple antigens. However, discerning protective effects can be difficult …

Background Virus-like particles have been regularly used as an antigen delivery system for
a number of Plasmodium peptides or proteins. The present study reports the immunogenicity …

Historically, vaccines have been designed to mimic the immunity induced by natural
exposure to the target pathogen, but this approach has not been effective for any parasitic …